FastWave Taking The Fast Way To Intravascular Lithotripsy
FastWave is developing an intravascular lithotripsy platform that will be differentiated from incumbent Shockwave Medical’s IVL platform and hopefully land its founders and investors a healthy return.
You may also be interested in...
JPM 2024 Roundup: Abbott And Medtronic Push Diabetes Tech, Edwards Updates Tricuspid Progress, Shockwave Bets On R&D
Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.
Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.
Freenome, the Roche-backed early cancer detection liquid biopsy developer has raised yet more money, making it one of the best-funded companies in its sub-sector. With trial results due relatively soon, investors are likely hoping this will be the last funding round required before full commercialization.